The diagnosis and management of chronic myelogenous leukemia (CML) follow a clear path. A blood count showing a very high white cell count raises suspicion, testing for the BCR-ABL1 fusion gene confirms it, and daily tyrosine kinase inhibitor (TKI) tablets control the disease in most people. With regular molecular monitoring, most patients diagnosed in the chronic phase can now expect a near-normal life expectancy, and some can eventually stop treatment altogether.
What Is Chronic Myelogenous Leukemia?
Chronic myelogenous leukemia, also called chronic myeloid leukemia, is a cancer of the blood-forming stem cells in the bone marrow. It is classed as a myeloproliferative neoplasm, meaning the marrow overproduces myeloid cells, especially granulocytes.
The hallmark of CML is the Philadelphia chromosome. It forms when pieces of chromosomes 9 and 22 swap places, a change written as t(9;22). This joins the BCR gene to the ABL1 gene, creating a fusion gene that makes a permanently “switched on” tyrosine kinase. That enzyme drives the cells to keep dividing and resist normal cell death.
CML is most often diagnosed in middle-aged and older adults and is slightly more common in men. The only well-established environmental risk factor is exposure to high doses of ionizing radiation. It is not inherited, and nothing a patient did caused it.
Symptoms and the Three Phases of CML
Many people have no symptoms at all and are diagnosed after a routine blood test. When symptoms occur, they are usually vague: fatigue, weight loss, night sweats, and a feeling of fullness under the left ribs from an enlarged spleen.
Without effective treatment, CML moves through phases. Knowing the phase matters because it changes both treatment and outlook.
| Phase | What it means | Typical features |
|---|---|---|
| Chronic phase | Early, stable disease; where most patients are diagnosed | High white count with mature cells, few blasts, often an enlarged spleen |
| Accelerated phase | Disease becoming less controlled | Rising blasts or basophils, falling or very high platelets, new chromosome changes |
| Blast phase | Transformation into an acute leukemia | Blasts at 20% or more in blood or marrow; behaves like acute myeloid or lymphoblastic leukemia |
Modern TKI therapy has made progression from chronic phase uncommon, which is one of the biggest successes in cancer medicine.
How CML Is Diagnosed
CML diagnosis uses a small set of well-defined tests. Our guide to leukemia diagnosis tests covers them in more depth; here is how they apply to CML.
Complete blood count and blood smear
The complete blood count (CBC) usually shows a markedly raised white cell count. The smear shows granulocytes at every stage of maturation, often with increased basophils and eosinophils. Platelets are frequently high, and mild anemia is common.
Bone marrow aspiration and biopsy
A marrow sample confirms the phase by counting blasts and allows a full karyotype. The karyotype identifies the Philadelphia chromosome and any additional chromosome changes, which carry prognostic weight.
FISH and quantitative PCR
FISH (fluorescence in situ hybridization) detects the BCR-ABL1 fusion directly. Quantitative PCR (qPCR) measures how much BCR-ABL1 message is present in the blood. The baseline qPCR result becomes the reference point for all future monitoring.
Doctors also calculate a risk score, such as the Sokal or ELTS score, from age, spleen size, platelet count, and blast percentage. The score helps guide the choice of first TKI.
Management: Tyrosine Kinase Inhibitors
TKIs block the abnormal BCR-ABL1 enzyme and are the foundation of CML treatment. Several are available, and the choice depends on the risk score, other health conditions, side-effect profile, and cost.
- Imatinib: the first TKI; well tolerated long term. Common effects include fluid retention around the eyes, muscle cramps, and nausea.
- Dasatinib: a more potent second-generation drug; can cause fluid around the lungs (pleural effusion).
- Nilotinib: must be taken on an empty stomach; can raise blood sugar and cholesterol and prolong the QT interval on the ECG.
- Bosutinib: diarrhea is common early on; liver tests need checking.
- Ponatinib: active against the resistant T315I mutation; carries a higher risk of arterial blood clots.
- Asciminib: works at a different site on the BCR-ABL1 protein and is used after other TKIs or for T315I.
Taking the tablet every day matters. In my practice, missed doses are one of the most common reasons for a disappointing response, so we discuss routines, side effects, and drug interactions at every visit.
Monitoring Response and Treatment-Free Remission
Response is tracked with qPCR on the international scale (IS), usually every three months until the response is stable. The main milestones are summarized below.
| Time on TKI | Optimal BCR-ABL1 (IS) |
|---|---|
| 3 months | 10% or less |
| 6 months | 1% or less |
| 12 months | 0.1% or less (major molecular response) |
Missing a milestone or a rising level prompts a check of adherence and a test for kinase domain mutations, which can guide a switch to another TKI. Patients who fail several TKIs, or who present in blast phase, may be considered for allogeneic stem cell transplant, the only established curative option.
Some patients who reach a sustained deep molecular response after several years of treatment can try stopping their TKI under close supervision. This is called treatment-free remission. Monthly qPCR is needed at first, and if levels rise, restarting the TKI usually restores control. For how CML fits into leukemia care more broadly, see our overview of leukemia diagnosis and management and our leukemia guide.
Key Takeaways
- CML is driven by the BCR-ABL1 fusion gene from the Philadelphia chromosome.
- Diagnosis rests on the CBC, bone marrow examination, karyotype, FISH, and qPCR.
- TKIs taken daily control the disease in most patients diagnosed in chronic phase.
- Regular qPCR monitoring against set milestones is the backbone of management.
- Selected patients with deep, lasting responses may stop treatment safely under supervision.
- See your hematologist promptly for new left-sided abdominal fullness, fevers, bleeding, or bone pain while on treatment.
Frequently Asked Questions
Is chronic myelogenous leukemia curable?
Allogeneic stem cell transplant can cure CML, but it is reserved for selected patients because of its risks. For most people, TKIs provide long-term control that allows a near-normal life. A proportion of patients reach treatment-free remission, which some describe as a functional cure.
Will I need to take TKI tablets for life?
Many patients do, but not all. Those who achieve a stable deep molecular response for a sustained period may be offered a trial off treatment. This must only be done with frequent qPCR monitoring in a specialist setting.
How often will I need blood tests?
Early on, blood counts are checked often and qPCR is usually done every three months. Once a stable major molecular response is reached, qPCR intervals may lengthen. After stopping a TKI, testing becomes more frequent again.
Can I have children while on treatment for CML?
TKIs can harm a developing baby, so pregnancy needs careful planning with your hematologist. Men on imatinib have generally fathered children without problems, but the plan should still be discussed. Some women pause treatment around conception under close supervision.
